

chips, EDC-NHS conjugation, and BIAevaluation software. Technical details have been described previously (37).

ELISA

- Protein or peptide ELISA

96-well half-area microtiter plates (Costar, USA) were coated with 30 μ L/well of 1 μ g/mL recombinant NY-ESO-1 protein, or 10 μ g/mL 20-mer peptides spanning the entire NY-ESO-1 protein (Peptides & Elephants, Germany) diluted in PBS overnight at 4°C. After coating, plates were washed with PBS + 0.05% Tween-20 (PBS-T) and blocked for 1 h at room temperature with 2% BSA/PBS (Sigma). B cell-conditioned medium, patient serum, or recombinant antibody was incubated for 2 h at room temperature (RT) at indicated concentrations or dilutions in PBS. Plates were washed with PBS-T and incubated for 1 h at RT with HRPO-conjugated goat-anti-human Fc γ antibody (Jackson ImmunoResearch), diluted 1:4000 in 0.5% BSA/PBS, followed by measurement of the HRPO activity using a TMB substrate solution (Sigma, Buchs, Switzerland). The mouse IgG1 monoclonal anti-NY-ESO-1 antibody E978 (38) and HRPO-conjugated goat-anti-mouse Fc γ antibody (Jackson ImmunoResearch) at 1:4000 dilution in 0.5% BSA/PBS served as positive control.

- Cellular ELISA

4 x 10⁴ SK-MEL-37 cells were seeded in a 96-well flat bottom plate and cultured under standard conditions overnight. Cells were fixed in ice-cold ethanol/acetone mix (1:1) for 15 min on ice. After two wash steps with PBS, cells were blocked and permeabilized with 100 μ L of PBS + 0.5% BSA + 0.5% Triton X 100 for 2 h at 4°C. B cell-conditioned medium or recombinant antibody was incubated at indicated concentrations for 2 h at 4°C. Bound antibodies were detected after 1 h incubation at 4°C with HRPO-labeled goat anti-human Fc secondary antibody (Jackson ImmunoResearch).

Immunoprecipitation

SK-MEL-37 tumor cells were lysed with Triton X 100/Glycerol-based lysis buffer for 15 min at 4°C. Cell debris was separated by centrifugation at maximum speed in a table centrifuge and protein concentration of the supernatant analyzed by standard Bradford assay. 300 ng of antibody was used to precipitate NY-ESO-1 from 250 μ g of SK-MEL-37 cell lysate in a 16 h incubation at 4°C. The immune complex was isolated by adding magnetic Protein G beads (New England Biolabs, Ipswich, MA) for 1 h at 4°C under constant agitation. Beads were washed, resuspended in NuPAGE LDS sample buffer (Invitrogen) and boiled prior to Gradient SDS Polyacrylamide Gel Electrophoresis (NuPAGE 4-12% Bis-Tris Gel, Invitrogen). NY-ESO-1 protein was detected by Western blot using murine antibody E978 (38).

In vitro cross-presentation assay

Human, HLA-A*0201/NY-ESO-1₁₅₇₋₁₆₅ specific CD8⁺ T cells were cloned as previously described (39). To generate DCs, CD14⁺ cells were MACS-purified according to the manufacturer's instructions (Miltenyi Biotec) from PBMC from HLA-A*0201+ healthy donors and cultured at 10⁶ cells/mL in serum-free CellGro DC media (CellGenix), supplemented with 800 U/mL GM-CSF and 500 U/mL IL-4 (R&D Systems) to generate DCs. Medium was exchanged the following day and DCs were harvested on d 4 of culture and resuspended at 10⁶/mL in Opti-MEM (Gibco). Immune complexes were generated by incubating 20 μ g recombinant NY-ESO-1 with 200 μ g 12D7 in a total volume of 500 μ L Opti-MEM (Gibco) for 30 min at

37°C. Human IgG1 (Sigma Aldrich), 12D7 alone, or NY-ESO-1 alone were used as controls. Alternatively, 200 μ g 12D7 was incubated with a lysate of an equivalent of 10⁷ NY-ESO-1+ SK-MEL-37 cells in 500 μ L Opti-MEM. DCs (5x10⁵ in 0.5 mL Opti-MEM) were added to the immune complexes and controls. The mixture was incubated at 37°C for 3 h. DCs were then centrifuged and resuspended in CellGro DC media at 10⁶/mL. Hundred μ L (10⁵ DCs) were cultured in 96-well flatbottom plates at 37°C in the presence or absence of maturation cocktail (1 μ g/mL soluble CD40L (sCD40L) trimer (PeproTech) plus TNF- α (25 ng/mL; R&D Systems)). After 36 h, approximately 6 x 10⁵ HLA-A*0201/NY-ESO-1₁₅₇₋₁₆₅ specific CD8⁺ T cells in 100 μ L RPMI + 10% human serum + antibiotics + 20 μ g/mL Brefeldin A (Sigma Chemicals) were added to the different DC-cultures. After 4 h, cultures were harvested in FACS buffer (PBS + 2% FCS + 2 mM EDTA + 0.05% NaN₃) and surface stained with anti-CD8 followed by intracellular staining for IFN- γ as previously described (39). CD8⁺ T cells plus unloaded DCs served as negative control, and CD8⁺ T cells plus DCs with 10⁻⁶ M of NY-ESO-1₁₅₇₋₁₆₅ (SLLMWITQC, Thermo Fisher Scientific) served as positive control. All cultures were performed at least in duplicates.

Mice and cell lines

BALB/c mice were originally obtained from Jackson Laboratories and were bred and kept under specific pathogen-free conditions in the Institute of Laboratory Animal Sciences (University of Zürich). Age- and sex-matched mice of 9-12 weeks old were used for all experiments. Mice were housed under specific pathogen-free conditions at University Hospital Zürich. All experiments were performed in agreement with the federal and cantonal laws on animal protection.

The colon carcinoma cell line CT26 was transfected to stably express intracellular NY-ESO-1 (40) and was cultured in RPMI + 10% FCS + antibiotics + 10 μ g/mL puromycin under standard tissue culture conditions. CT26/NY-ESO-1 and the human melanoma cell line SK-MEL-37 were cultured in RPMI + 10% FCS + antibiotics under standard tissue culture conditions. 293-T cells were cultured in DMEM (Lonza, Switzerland) supplemented with 10% FCS (Linaris) and 10 U penicillin-streptomycin (Lonza, Switzerland) under standard tissue culture conditions.

Treatment of mice

Mice were injected s.c. into the right flank with 10⁶ CT26/NY-ESO-1+ cells in 100 μ L RPMI. The tumor surface was measured at least twice a week with a calliper. Treatment was started (d 0) when tumors reached a size of approximately 25 mm². 5-Fluorouracil (5-FU, TEVA Pharma, Aesch, Switzerland) was diluted in saline and were given i.p. on d 0 and d 7 at 75 mg/kg, respectively. 12D7 (100 μ g in 100 μ L PBS) was given i.p. on d 2 and d 9. All animal experiments were performed in accordance with the Swiss federal and cantonal law on animal protection.

Flow cytometry

At the end of the experiment (1 week after the last injection of 12D7), mice were injected i.p. with 250 μ g Brefeldin A and were euthanized 4 h later. Subsequent processing and staining was performed in the presence of 10 μ g/mL Brefeldin A (25). Tumors were cut into small pieces and subsequently digested with 1.5 mg/mL collagenase + 100 μ g/mL DNase for 1 h at 37°C followed by filtration through a 50 μ m cell strainer. Single cell suspensions were surface stained in FACS buffer (FB, PBS + 2% FCS + 0.03% NaN₃ + 20 mM EDTA) with anti-CD45.2 pacific

blue and anti-CD8bPE. For intracellular staining to detect IFN- γ , cells were permeabilized with permeabilization buffer (PB, FB + 0.1% saponin) and stained intracellularly with anti-IFN- γ APC. All antibodies were obtained from BioLegend, San Diego, CA, USA. Samples were measured with a CyAn ADP9 (Beckman Coulter, Brea, CA, USA) and analyzed using FlowJo Analysis Software (Tree Star Inc., Ashland, OR, USA).

Statistical analysis

Statistics were done using an unpaired Student two-tailed *t*-test. Error bars represent SD. *p* values less than 0.05 were considered significant.

Contact

Address correspondence to:

Prof. Dr. Maries van den Broek
Department of Oncology
University Hospital Zürich
Rämistrasse 100
CH-8091 Zürich
Switzerland
Tel.: + 41 11 556 31 34
E-mail: Maries@van-den-broek.ch

Cell surface antigens: invaluable landmarks reflecting the nature of cells

Toshitada Takahashi¹ and Hiroshi Shiku²

¹Comprehensive Health Science Center, Aichi Health Promotion Foundation, Higashiura Town, Aichi, Japan

²Department of Cancer Vaccine and Immuno-Geno Therapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan

Keywords: cell surface antigens, leukemia, Lyt antigen, TL antigen, Lloyd Old

Although Lloyd J. Old was involved in various studies of the interactions between cancer and the immune system, it seems to us that his ideas often originated from the studies of serological identification of mouse lymphocyte antigens. The findings from these studies allow us to distinguish cells of different lineages and differentiation stages, and also to distinguish leukemia cells from normal lymphocytes (1). It is amazing that essentially a single serological technique, i.e., the Trypan blue exclusion test (presumably introduced in Peter Gorer's laboratory by Edward A. Boyse), was used to define a series of these antigens. This technique was used in conjunction with absorption analysis to elucidate the specificity of antisera, based on a vast knowledge of mouse immunogenetics. In the laboratory, Elisabeth Stockert (who was a technical assistant at that time) was the great master of these serological techniques, carrying out her own projects of cell surface antigens, as will be described below, while managing the day-to-day business of the laboratory. Similarly, Elizabeth A. Carswell and Gayla Geering investigated tumor necrosis factor (TNF) and retrovirus-associated intracellular antigens, respectively, while working as technical assistants.

When Toshitada Takahashi left Nagoya, Japan, for New York in 1968, the TL and Lyt (Ly) series of antigens of thymocytes and peripheral T cells had already been identified by Drs. Old, Boyse, and Stockert (1-3), and congenic strains of mice for each antigen system had been established. Contemporaneously, Katsuaki Itakura was preparing to initiate genetic linkage studies of these differentiation antigens. In the late 1960s, the concept of T cells and B cells was becoming more and more widespread, and after the First International Immunology Congress in Washington, D.C., in 1971, this concept became widely accepted all over the world. The Thy-1 (Θ, CD90) and Lyt series of antigens are considered to be markers for thymocytes and peripheral T cells, whereas TL is a marker for thymocytes. Thus, Takahashi's project was focused on B cells. When he started his study on cell surface antigen analysis of plasma cell leukemias (PCL), Yoshiyuki Hashimoto kindly taught him how to carry out day-to-day experiments. At that time, Dr. Hashimoto was a visiting investigator from the Biochemistry Institute in Tokyo, Japan, working on cell-mediated immunity against TL-positive leukemias. It is noteworthy that, as the founder of the Japanese Association of Cancer Immunology, Dr. Hashimoto greatly contributed to the progress in tumor immunology in Japan. Dr. Takahashi defined a novel PC.1 alloantigen that is expressed on

PCL cells and mature antibody-forming cells (IgG type hemolytic plaque-forming cell, IgG-PFC), but not on peripheral B cells (4). Furthermore, he demonstrated reciprocal expression of surface immunoglobulin, which is expressed on peripheral B cells, but on neither IgG-PFC nor PCL cells. We had to wait until 1973 to see the first report of a B cell alloantigen by Hidetoshi Sato (5), although it is named Lyb-2 (CD72). This protein was later shown to be a ligand for Lyt-1 (CD5) and appears to be present on all B lymphocytes except for plasma cells.

In 1973, Hiroshi Shiku, also from Nagoya, went to the Sloan-Kettering Institute for Cancer Research (SKI) and started working on cell-mediated immunity with Herbert F. Oetgen and Michael A. Bean. Although the chromium release assay had already been established by Cerottini *et al.* and was widely used to target suspension cells, this assay was not always suitable for monolayer cell cultures derived from solid tumors. In order to detect killing activity against attached target cells, Dr. Bean developed a new microassay using [3H]proline for labeling, instead of chromium 51; this assay was used by Dr. Shiku for his phenotype analysis of T cell subpopulations. A very exciting result was obtained in 1975, namely, that the killer T cell population is relatively rich in Lyt-2/3 (CD8) surface antigens, but relatively poor in Lyt-1 antigen, suggesting that T cells with different functions could be distinguished on the basis of their Lyt phenotypes (6). Subsequently, Eiichi Nakayama clearly demonstrated selective blocking of cytotoxic cells by Lyt-2 and Lyt-3 antisera *in vitro* in the absence of complement, suggesting that Lyt-2/3 determinants on the surface of cytotoxic T cells have a close spatial relationship to the T cell receptor (7, 8). Furthermore, it was shown later by Drs. Nakayama and Akiko Uenaka in Japan that *in vivo* administration of Lyt-2/3 antibodies is able to block the cytotoxicity of killer T cells responsible for tumor rejection (9). Thus, Lyt-2/3 was demonstrated to be not merely the marker of killer T cells, but a molecule that is important to their key function. As for the phenotype of effector cells (Th1) and regulatory T cells (Treg), Shimon Sakaguchi and his colleagues demonstrated in 1982 that both populations express Lyt-1, but not Lyt-2/3, i.e., the CD4 phenotype (10, 11); they accomplished this by analysis of an organ-localized autoimmune disease model that develops in mice thymectomized on day 3 after birth. It is now well known that CD8 and CD4 molecules are involved, respectively, in the interactions between T cell receptor and target antigen peptides presented on major histocompatibility complex (MHC) class I and class II molecules. This research laid the groundwork for identifying the cell surface markers that allow cells to be experimentally and diagnostically separated and distinguished,

revolutionizing immunology and medicine as it is practiced today.

Unlike the Lyt series of antigens, the TL antigen system has unique characteristics, e.g., TL expression is restricted to thymocytes in certain (TL⁺) strains of the mouse, indicating a character of differentiation antigens, whereas TL appears in a proportion of T cell leukemias (lymphomas) developed even in TL⁻ strains that normally never express TL during fetal or adult life; these can be regarded as leukemia-specific antigens. Yuichi Obata, who worked with Dr. Old for 12 years, succeeded in 1985 in cloning genomic TL genes as members of MHC genes of chromosome 17 (12). These may be regarded as the first set of cloned genes encoding tumor antigen; the P815 mast cell tumor antigen gene, *PIA*, was reported by Boon's group in 1991. In 1985, Dr. Obata then returned to Japan to be a staff member at the Aichi Cancer Center Research Institute in Nagoya, where he continued his TL project. One of the interesting findings obtained thereafter is that when a chemical carcinogen (NBU) was administered to C57BL/6 and C3H strains, T cell leukemia development was slower than in T3B-TL gene-transduced counterpart strains expressing TL ubiquitously as self antigens, suggesting that anti-TL immunity may play a protective role in immune surveillance (13). Another important finding is that immunization with TL-positive skin from T3B-TL transgenic mice produced cytotoxic T cells exhibiting TL- (but not H-2-) restriction (14). This indicated that TL antigen is a transplantation antigen, although in the 1970s it was considered to be a serologically defined antigen.

In the late 1960s and early 1970s, cancer research focused on viral carcinogenesis, since the Epstein-Barr virus (EBV) had been discovered as a candidate for human tumor virus, while retroviruses such as murine leukemia virus (MuLV) and murine mammary tumor virus (MTV) had been shown to be associated with development of murine leukemia and mammary tumor, respectively. In Dr. Old's laboratory, cell surface and intracellular antigens of MuLV and MTV were extensively studied, and many antigenic systems were defined. Particularly, detailed analyses of the relationship between gp70 of MuLV classes and cell surface antigens were conducted by Drs. Stockert and Obata (15-18). Four antigens were defined as markers for each of the MuLV classes: GIX and G(RADAI) distinguished two types of ecotropic MuLV; G(ERLD) identified all xenotropic MuLV; and G(AKSL2) served as a marker for dual-tropic viruses in high-leukemia strains such as AKR mice. GIX antigen has characteristics of a differentiation antigen and is expressed on thymocytes in low-leukemia strains such as 129 mice; a linkage study conducted by Hisami Ikeda demonstrated that the antigen expression is controlled by linkage group 8 on chromosome 4 (19). During the course of these studies, Kouhei Kawashima obtained an interesting finding: thymocytes exhibit amplified expression of gp70-associated antigens during the late preleukemic period in the AKR strain, which is accompanied by the emergence of MuLVs with dual-tropic (but not ecotropic) properties (20, 21), leading to the belief that dual-tropic MuLVs are the proximal vectors of leukemogenesis in the AKR strain.

In addition to the studies of leukemia, an attempt was also made to detect individual antigens of chemically induced mouse sarcomas by use of the complement-dependent cytotoxicity microassay. The presence of such antigens was demonstrated in the 1960s by *in vivo* transplantation experiments, but the nature of the antigens was not well understood. In 1977, Albert B. DeLeo produced antisera that detected antigens with an exceedingly restricted distribution on two BALB/c methylcholanthrene-induced sarcomas, Meth A and CMS4

(22). During the course of these studies, he defined a transformation-related intracellular antigen of sarcomas and leukemias with a molecular weight of 53 kilodaltons (23); this antigen is now known to be the product of the *p53* tumor suppressor gene. Two genes encoding for individual transplantation antigens detected by cytotoxic T cells were subsequently isolated in Japan from different tumors: *RAMP* (exon extension mutation) from Meth A, by Dr. Nakayama in 2003 (24), and *ERK2* (point mutation) from another sarcoma, CMS5, by Hiroaki Ikeda *et al.* in 1997 (25). To date, the relationship between these gene products and the serologically defined antigens has not been elucidated.

Here, we have only introduced a part of the mouse cell surface antigen studies initiated at SKI, and briefly discussed their further development in Japan. It is noteworthy that not only genes encoding these antigens, but also fertilized eggs of the pertinent congenic and transgenic mouse strains are maintained even now at the BioResource Center of Riken Tsukuba Institute (director, Dr. Obata), and are available to researchers interested in this field.

References

1. Old LJ. Cancer immunology: The search for specificity—G.H.A. Clowes Memorial lecture. *Cancer Res* 1981; **41**: 361-375. (PMID: 7004632)
2. Boyse EA, Old LJ. Some aspects of normal and abnormal cell surface genetics. *Annu Rev Genet* 1969; **3**: 269-290. (PMID: not available)
3. Old LJ, Stockert E. Immunogenetics of cell surface antigens of mouse leukemia. *Annu Rev Genet* 1977; **11**: 127-160. (PMID: 202188)
4. Takahashi T, Old LJ, McIntire KR, Boyse EA. Immunoglobulin and other surface antigens of cells of the immune system. *J Exp Med* 1971; **134**: 815-832. (PMID: 4106485)
5. Shiku H, Kisielow P, Bean MA, Takahashi T, Boyse EA, Oettgen HF, Old LJ. Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity *in vitro*. Evidence for functional heterogeneity related to the surface phenotype of T cells. *J Exp Med* 1975; **147**: 227-241. (PMID: 1078839)
6. Sato H, Boyse EA. A new alloantigen expressed selectively on B cells: the Lyb-2 system. *Immunogenetics* 1976; **3**: 565-572. (PMID: not available)
7. Nakayama E, Shiku H, Stockert E, Oettgen HF, Old LJ. Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. *Proc Natl Acad Sci U S A* 1979; **76**: 1977-1981. (PMID: 88050)
8. Nakayama E, Dippold W, Shiku H, Oettgen HF, Old LJ. Alloantigen-induced T-cell proliferation: Lyt phenotype of responding cells and blocking of proliferation by Lyt antisera. *Proc Natl Acad Sci U S A* 1980; **77**: 2890-2894. (PMID: 6967215)
9. Nakayama E, Uenaka A. Effect of *in vivo* administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. *J Exp Med* 1985; **161**: 345-355. (PMID: 3871834)
10. Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of

- Lyt-1 effector cells for oocytes damage after adoptive transfer. *J Exp Med* 1982; **156**: 1565-1576. (PMID: 6983557)
11. Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in postthymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. *J Exp Med* 1982; **156**: 1577-1586. (PMID: 6983558)
 12. Obata Y, Chen YT, Stockert E, Old LJ. Structural analysis of TL genes of the mouse. *Proc Natl Acad Sci U S A* 1985; **82**: 5475-5479. (PMID: 2410925)
 13. Tsujimura K, Obata Y, Matsudaira Y, Ozeki S, Nishida K, Okanami Y, Akatsuka Y, Kuzushima K, Takahashi T. Immunity against mouse thymus-leukemia antigen (TL) protects against development of T lymphomas induced by a chemical carcinogenic agent, N-butyl-N-nitrosourea. *Cancer Sci* 2004; **95**: 914-919. (PMID: 1554651)
 14. Tsujimura K, Obata Y, Takahashi T. Thymus-leukemia antigen (TL) as a major histocompatibility complex (MHC) class Ib molecule and tumor-specific antigen. *Cancer Sci* 2004; **95**: 469-474. (PMID: 15182425)
 15. Stockert E, Old LJ, Boyse EA. The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. *J Exp Med* 1971; **133**: 1334-1355. (PMID: 5576334)
 16. Obata Y, Stockert E, O'Donnell PV, Okubo S, Synder HW Jr., Old LJ. G(RADA1): a new cell surface antigen of mouse leukemia defined by naturally occurring antibody and its relationship to murine leukemia virus. *J Exp Med* 1978; **147**: 1089-1105. (PMID: 206645)
 17. Stockert E, DeLeo AB, O'Donnell PV, Obata Y, Old LJ. G(AKSL2): a new cell surface antigen of the mouse related to the dualtropic mink cell focus-inducing class of murine leukemia virus detected by naturally occurring antibody. *J Exp Med* 1979; **149**: 200-215. (PMID: 216764)
 18. Obata Y, Stockert E, DeLeo AB, O'Donnell PV, Snyder HW Jr, Old LJ. A cell surface antigen of the mouse related to xenotropic MuLV defined by naturally occurring antibody and monoclonal antibody. Relation to Gix G(rada1), G(aksl2) systems of MuLV-related antigens. *J Exp Med* 1981; **154**: 659-675. (PMID: 6268731)
 19. Ikeda H, Stockert E, Rowe WP, Boyse EA, Lilly F, Sato H, Jacobs S, Old LJ. Relation of chromosome 4 (linkage group 8) to murine leukemia virus-associated antigens of AKR mice. *J Exp Med* 1973; **137**: 1103-1107. (PMID: 4348279)
 20. Kawashima K, Ikeda H, Hartley JW, Stockert E, Rowe WP, Old LJ. Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. *Proc Natl Acad Sci U S A* 1976; **73**: 4680-4684. (PMID: 188051)
 21. Kawashima K, Ikeda H, Stockert E, Takahashi T, Old LJ. Age-related changes in cell surface antigens of preleukemic AKR thymocytes. *J Exp Med* 1976; **144**: 193-208. (PMID: 180229)
 22. DeLeo AB, Shiku H, Takahashi T, John M, Old LJ. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. *J Exp Med* 1977; **146**: 720-734. (PMID: 197192)
 23. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcoma and other transformed cells of the mouse. *Proc Natl Acad Sci U S A* 1979; **76**: 2420-2424. (PMID: 221923)
 24. Uenaka A, Nakayama E. Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL). *Cancer Sci* 2003; **94**: 931-936. (PMID: 14611667)
 25. Ikeda H, Ohta N, Furukawa K, Miyazaki H, Wang L, Kuribayashi K, Old LJ, Shiku H. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. *Proc Natl Acad Sci U S A* 1997; **94**: 6375-6379. (PMID: 9177225)

Contact

Address correspondence to:

Toshitada Takahashi, M.D.
 Comprehensive Health Science Center
 Aichi Health Promotion Foundation
 1-1 Aza Gengoyama, Oaza Morioka
 Higashiura Town, Aichi
 Japan
 Tel.: + 81 0562 82 011
 E-mail: t.toshi@festa.ocn.ne.jp

Keywords: surgical treatment; detection marker; follow-up marker; recurrence; prognosis

NY-ESO-1 antibody as a novel tumour marker of gastric cancer

S Fujiwara¹, H Wada^{*1}, J Kawada¹, R Kawabata¹, T Takahashi¹, J Fujita², T Hirao³, K Shibata³, Y Makari⁴, S Iijima⁴, H Nishikawa⁵, A A Jungbluth⁶, Y Nakamura¹, Y Kurokawa¹, M Yamasaki¹, H Miyata¹, K Nakajima¹, S Takiguchi¹, E Nakayama⁷, M Mori¹ and Y Doki¹

¹Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita-city (E-2), Osaka 565-0871, Japan; ²Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka-city, Osaka 560-0055, Japan; ³Surgery, Ikeda City Hospital, 3-1-18 Jonan, Ikeda-city, Osaka 563-8510, Japan; ⁴Surgery, Minoh City Hospital, 5-7-1 Kayano, Minoh-city, Osaka 562-0014, Japan; ⁵Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan; ⁶Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA and ⁷Faculty of Health and Welfare, Kawasaki University of Medical Welfare, 288 Matsushima, Kurashiki-city, Okayama 701-0193, Japan

Background: NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer.

Methods: Sera from 363 gastric cancer patients were screened by enzyme-linked immunosorbent assay (ELISA) to detect NY-ESO-1 antibodies. Serial serum samples were obtained from 25 NY-ESO-1 antibody-positive patients, including 16 patients with curative resection and 9 patients who received chemotherapy alone.

Results: NY-ESO-1 antibodies were detected in 3.4% of stage I, 4.4% of stage II, 25.3% of stage III, and 20.0% of stage IV patients. The frequency of antibody positivity increased with disease progression. When the NY-ESO-1 antibody was used in combination with carcinoembryonic antigen and CA19-9 to detect gastric cancer, information gains of 11.2% in stages III and IV, and 5.8% in all patients were observed. The NY-ESO-1 immune response levels of the patients without recurrence fell below the cutoff level after surgery. Two of the patients with recurrence displayed incomplete decreases. The nine patients who received chemotherapy alone continued to display NY-ESO-1 immune responses.

Conclusion: When combined with conventional tumour markers, the NY-ESO-1 humoral immune response could be a useful tumour marker for detecting advanced gastric cancer and inferring the post-treatment tumour load in seropositive patients.

Gastric cancer is the second most common cause of cancer-related death worldwide (Statistics and Information Department, 2006; Katanoda and Yako-Suketomo, 2009). Although complete removal of the tumour by surgical resection is an ideal treatment option for patients with gastric cancer, many patients with advanced-stage gastric cancer need to be treated with intensive chemotherapy. Gastric cancer patients exhibit high relapse rates even after curative surgery and unresponsiveness to chemotherapy, resulting in dismal survival rates (Sasako *et al*, 2011). Several methods for the prediction and early detection of subclinical 'minimal residual

cancer' after surgery (Austrup *et al*, 2000; Klein *et al*, 2002) or relapse have been developed, for example, peritoneal lavage, positron emission tomography, gene profiling, and so on. (Motoori *et al*, 2006; Makino *et al*, 2010; Graziosi *et al*, 2011), reliable markers that can specifically reflect gastric cancer disease status have not been determined.

Analysing serum level of tumour markers is employed for cancer detection, monitoring patients' disease status, and prognosis prediction. Several organ-specific tumour markers are used in the clinic, for example, prostate-specific antigen and prostatic acid

*Correspondence: Dr H Wada; E-mail: hwada@gesurg.med.osaka-u.ac.jp

Received 29 June 2012; revised 9 January 2013; accepted 16 January 2013

© 2013 Cancer Research UK. All rights reserved 0007–0920/13

phosphatase for prostate cancer (Seamonds *et al*, 1986; Ferro *et al*, 1987) and protein induced by vitamin K absence-II for liver cancer (Fujiyama *et al*, 1986). As no gastric cancer-specific markers have been determined, a combination of several nonspecific tumour markers, for example, carcinoembryonic antigen (CEA), CA19-9, and so on, is merely applicable for monitoring treatment efficacy, but not the diagnosis of gastric cancer (Takahashi *et al*, 1995, 2003). Carcinoembryonic antigen and CA19-9 are found in the sera of 20–60% of gastric cancer patients, and their expression levels in gastric cancer are related to clinical events, such as relapse (Kodera *et al*, 1996). Carcinoembryonic antigen value, in particular, is indicative of the formation of a large tumour, liver or peritoneal metastasis, and/or a high risk of relapse and poor prognosis (Ikeda *et al*, 1993; Yamamoto *et al*, 2004). However, as CEA, a cell surface-anchored glycoprotein, is expressed in normal cell membranes, 5% of CEA-positive cases are pseudopositives, that is, caused by heavy smoking, endometriosis, and ageing, and so on. (Alexander *et al*, 1976), suggesting the importance of novel markers for gastric cancer.

NY-ESO-1 antigen, a cancer/testis (CT) antigen, was originally identified in oesophageal cancer by serological expression cloning using autologous patient serum and has been shown to be strongly immunogenic. Spontaneous NY-ESO-1 antibody production is often observed in patients with NY-ESO-1-expressing tumours, for example, 9.4% of melanoma patients, 12.5% of ovarian cancer patients, 7.7–26.5% of breast cancer patients, 4.2–20.0% of lung cancer patients, and 52% of prostate cancer patients, but has not been detected in non-cancerous donors (Stockert *et al*, 1998; Nakada *et al*, 2003; Türeci *et al*, 2006; Chapman *et al*, 2007; Isobe *et al*, 2009; Gati *et al*, 2011). Thus, it is possible that the NY-ESO-1 humoral immune response could be used as a serological marker for detecting these cancers and to facilitate the clinical management of some patients with particular types of cancer (Gnjatic *et al*, 2006). Jäger *et al* (1999) found that the change in the NY-ESO-1 humoral immune response reflected the overall tumour load in 10 out of 12 patients with various cancers. However, there is ongoing controversy regarding the association between the NY-ESO-1 immune response and prognostic criteria (Yuan *et al*, 2011). To address these issues in gastric cancer, we investigated the clinical usefulness of the NY-ESO-1 humoral immune response for diagnosis, monitoring, and relapse prediction in gastric cancer patients.

MATERIALS AND METHODS

Serum sample and tissue specimen collection from gastric cancer patients. In all, 363 patients with histologically confirmed gastric cancer, who underwent surgical resection or chemotherapy at one of four institutions between 2004 and 2011, were included in this study after providing written informed consent. Serum samples were obtained from the 363 patients during their admission to hospital for surgical treatment and/or chemotherapy, and afterwards, serial serum samples were obtained at each follow-up visit from 25 patients who displayed NY-ESO-1 humoral immune responses. All serum samples were collected as surplus samples after routine blood tests and stored. Fixed and frozen gastric cancer tissue samples were obtained from 60 out of 363 patients during surgery and stored. The samples were subsequently subjected to expression analysis. Information regarding blood test results, tumour stage, histological type, depth of invasion, lymph node metastasis, and distant metastasis, which were obtained from pathological examinations and CT scans, were collected from the relevant patient databases. Serum samples obtained from 50 healthy donors were used as controls. This study was approved by the institutional review boards of Osaka University Hospital,

Toyonaka Municipal Hospital, Ikeda City Hospital, and Minoh City Hospital.

Reverse transcription-polymerase chain reaction. Total cellular RNA was extracted from the frozen tissue using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). The total RNA (1 µg) was subjected to the reverse transcription (RT) in 20 µl buffer with oligo-(dT)₁₅ primer using a RT system (Promega, Madison, WI, USA). Conventional polymerase chain reaction (PCR) was performed in a 25-µl reaction mixture containing 1 µl of cDNA template, 500 nM of each primer, and 1 U of *Taq* DNA polymerase (AmpliTaq Gold, Roche Molecular Systems, Pleasanton, CA, USA) in the following conditions: one cycle of 95 °C for 12 min; followed by 35 cycles of 94 °C for 1 min, 60 °C for 1 min, and 72 °C for 1.5 min; and then a final step of 72 °C for 10 min. The sequences of the primers for NY-ESO-1 were as follows: ESO1-1, 5'-AGTTC TACCTCGCCATGCCT-3'; and ESO1-2, 5'-TCCTCCTCCAGC GACAAACAA-3'. The integrity of each RNA sample was verified by performing RT-PCR for *porphobilinogen deaminase* (*PBGD*). The PCR products were subjected to electrophoresis on a 2% agarose gel and visualised with ethidium bromide.

Immunohistochemistry. Formalin-fixed, paraffin-embedded tissues were used for the immunohistochemistry (IHC) analyses. Slides were incubated with the primary antibody overnight at 4 °C. The monoclonal antibody E978, which was previously generated by our group, was used to detect NY-ESO-1. The slides were then subjected to a heat-based antigen retrieval technique by immersing them in a preheated buffer solution (hipH solution; Dako, Carpinteria, CA, USA). A polymer-based antibody detection system (PowerVision; Leica Microsystems, Buffalo Grove, IL, USA) was used as the secondary reagent, and 3,3-diaminobenzidine tetrahydrochloride (Liquid DAB; Biogenex, San Ramon, CA, USA) was used as the chromogen. Normal adult testis tissue as a positive control and appropriate negative controls were included for each case.

Enzyme-linked immunosorbent assay. A measure of 100 µl of 1 µg ml⁻¹ recombinant protein in coating buffer (pH 9.6) were added to each well of 96-well PolySorp immunoplates (Nunc, Roskilde, Denmark) and incubated overnight at 4 °C. The plates were then washed with PBS and blocked with 200 µl per well of 5% FCS/PBS for 1 h at room temperature. After being washed again, 100 µl of serially diluted serum were added to each well and incubated for 2 h at room temperature. Then, after extensive washing, goat anti-human IgG (Medical & Biological Laboratories, Nagoya, Japan) was added to the wells as a secondary antibody, and the plates were incubated for 1 h at room temperature. The plates were washed again, and the signals were developed with 100 µl per well of 0.03% *o*-phenylene diamine dihydrochloride, 0.02% hydrogen peroxide, and 0.15 M citrate buffer, and absorbance was read at 490 nm using an enzyme-linked immunosorbent assay (ELISA) reader (Benchmark Microplate Reader; Bio-Rad, Hercules, CA, USA). Ovalbumin (OVA; Sigma, St Louis, MO, USA) was used as the control protein. Levels of NY-ESO-1 humoral response were assessed using optical density (OD) values.

CEA and CA19-9. Serum CEA and CA19-9 levels were measured at each hospital's clinical laboratory department. Carcinoembryonic antigen and CA19-9 positivity were defined as serum levels of CEA and CA19-9 of >5.0 ng ml⁻¹ and >37 U ml⁻¹, respectively.

Statistical analysis. Fisher's exact test was used to assess the associations between NY-ESO-1 antibody expression and clinicopathological parameters. Kaplan-Meier curves were plotted to assess the effect of the NY-ESO-1 antibody on overall survival. Survival curves were compared using the log-rank test.

Table 1. Frequencies of NY-ESO-1 antibody, CEA, and CA19-9 in gastric cancer patients

Stage	NY-ESO-1 Ab	CEA	CA19-9	CEA and/or CA19-9	CEA and/or CA19-9 and/or NY-ESO-1 Ab
I	6/176 (3.4)	24/176 (13.6)	6/176 (3.4)	27/176 (15.3)	31/176 (17.6)
II	2/45 (4.4)	8/45 (17.8)	7/45 (15.6)	11/45 (24.4)	12/45 (26.6)
III	17/67 (25.3)	22/67 (32.9)	11/67 (16.4)	25/67 (37.3)	35/67 (52.2)
IV	16/75 (20.0)	23/75 (30.7)	30/75 (40.0)	40/75 (53.3)	46/75 (61.3)
I+II	8/221 (3.6)	32/221 (14.5)	13/221 (5.9)	38/221 (17.2)	43/221 (19.5)
III+IV	33/142 (23.2)	45/142 (31.7)	41/142 (28.9)	65/142 (45.8)	81/142 (57.0)
Total	41/363 (11.1)	77/363 (21.2)	54/363 (14.9)	103/363 (28.4)	124/363 (34.2)

Abbreviations: Ab = antibody; CA = carbohydrate antigen; CEA = carcinoembryonic antigen. Values within parentheses are percentages.

RESULTS

Determination of NY-ESO-1 humoral immune response positivity. We first determined the OD cutoff value for NY-ESO-1 humoral immune response positivity. When the serum samples from the 50 healthy donors were examined for reactivity to the NY-ESO-1 recombinant protein by ELISA, their OD values ranged from 0.08 to 0.20, and their mean and standard deviation values were 0.15 and 0.05, respectively, at a dilution of 1:200. Thus, NY-ESO-1 humoral immune response positivity was defined as an OD value of >0.25 at a dilution of 1:200 (95% accuracy level) and >3 times of the OD value against control protein (OVA).

NY-ESO-1 humoral immune responses of gastric cancer patients. Serum samples were obtained from 363 gastric cancer patients, including 176 stage I, 45 stage II, 67 stage III, and 75 stage IV patients at admission (Table 1). The NY-ESO-1 antibody was detected in 3.4% (6 of 176) of stage I, 4.4% (2 of 45) of stage II, 25.3% (17 of 67) of stage III, and 20.0% (16 of 75) of stage IV gastric cancer patients, resulting in an overall detection rate of 11.1% (41 of 363). An analysis of the gastric cancer patients' characteristics found that NY-ESO-1 antibody positivity was significantly correlated with gender (male>female) and tumour progression (Table 2). In particular, the patients with progressive gastric cancer involving deeper tumour invasion, positive lymph node metastasis, positive distant metastasis, or a higher clinical stage tended to produce the NY-ESO-1 antibody.

Analysis of NY-ESO-1 antigen expression. NY-ESO-1 mRNA and NY-ESO-1 protein expression were analysed by RT-PCR and IHC, respectively, in gastric cancer tissues obtained from 60 patients for whom both frozen and formalin-fixed specimens were available, including 12 stage I, 12 stage II, 20 stage III, and 16 stage IV patients (Table 3). NY-ESO-1 mRNA was detected in six specimens. NY-ESO-1 was immunohistochemically detected in 19 specimens, including 6 and 13 that were positive and negative for NY-ESO-1 mRNA, respectively. Most of the specimens displayed a heterogeneous staining pattern (data not shown).

NY-ESO-1 antibody and antigen expression. We analysed the frequency of NY-ESO-1 antibody positivity in gastric cancer patients in whom NY-ESO-1 antigen expression was or was not detected by RT-PCR or IHC. As shown in Table 3, 9 out of the 60 gastric cancer patients whose specimens were available for expression analysis possessed the NY-ESO-1 antibody in their sera. The NY-ESO-1 antibody was detected in 8 of 19 (42.1%) patients with IHC-positive gastric cancer and 5 of 6 (83.3%) patients with RT-PCR (and IHC)-positive gastric cancer, whereas only 1 of 41 patients in whom both RT-PCR and IHC analysis

Table 2. Relationship between NY-ESO-1 antibody positivity and clinicopathological features in gastric cancer patients

Variable	NY-ESO-1 Ab		P-value*
	Negative	Positive	
Gender			
Male	223 (86.4)	35 (13.6)	0.04307
Female	99 (94.3)	6 (5.7)	
Age (years)			
> 65	178 (88.6)	23 (11.4)	0.9209
< 65	144 (88.9)	18 (11.1)	
Histological type			
Differentiated	143 (89.4)	17 (10.6)	0.5605
Undifferentiated	132 (87.4)	19 (12.6)	
Depth of tumour invasion			
cT1-T2	193 (92.8)	15 (7.2)	0.0044
cT3-T4	129 (83.2)	26 (16.8)	
Lymph node metastasis			
Negative	196 (97.0)	6 (3.0)	<0.001
Positive	126 (78.3)	35 (21.7)	
Distant metastasis			
Negative	277 (91.1)	27 (8.9)	<0.001
Positive	45 (76.3)	14 (23.7)	
Stage			
I-II	213 (96.4)	8 (3.6)	<0.001
III-IV	109 (76.8)	33 (23.2)	

Abbreviations: Ab = antibody. Fisher's exact test was used for the statistical analysis. Values within parentheses are percentages.

produced negative results displayed an NY-ESO-1 humoral immune responses.

Frequencies of NY-ESO-1 humoral immune responses and conventional tumour markers in gastric cancer patients. The frequency of the NY-ESO-1 humoral immune response was compared with those of conventional tumour markers in gastric

Table 3. Frequency of NY-ESO-1 antibody positives in gastric cancer patients in whom the NY-ESO-1 antigen was or was not detected by IHC or RT-PCR

	IHC		
	Positive	Negative	Total
mRNA			
Positive	5/6 (83.3)	0/0 (0.0)	5/6 (83.3)
Negative	3/13 (23.1)	1/41 (2.4)	4/54 (7.4)
Total	8/19 (42.1)	1/41 (2.4)	9/60 (15.0)

Abbreviations: IHC = immunohistochemistry; RT-PCR = reverse transcription-polymerase chain reaction. Frozen and formalin-fixed tissue specimens from 60 patients, including 12 stage I, 12 stage II, 20 stage III, and 16 stage IV patients, were analysed. All stage IV patients had previously undergone surgical treatment. Values within parentheses are percentages.

cancer patients. The serum CEA and CA19-9 levels of 363 gastric cancer patients were measured at admission (Table 1). Carcinoembryonic antigen and CA19-9 positivity were observed in 21.2% (77 of 363) and 14.9% (54 of 363) of the gastric cancer patients, respectively, and, except for CA19-9 in the stage III patients, they displayed higher frequencies than the NY-ESO-1 humoral immune response in all stages of the disease. We then analysed whether the addition of the NY-ESO-1 humoral immune response to CEA and CA19-9 increased the diagnostic frequency of gastric cancer. The combined use of CEA and CA19-9 tests produced positivity rates of 15.3% (27 of 176) in stage I, 24.4% (11 of 45) in stage II, 37.3% (25 of 67) in stage III, and 53.3% (40 of 75) in stage IV gastric cancer patients, resulting in an overall positivity rate of 28.4% (103 of 363). When the NY-ESO-1 humoral immune response was added to these two conventional tumour markers, the positivity rates of all stages increased, resulting in information gains of 14.9% (from 25 to 35 patients; 10 of 67) in stage III and 11.2% (from 65 to 81 patients; 16 of 142) in stage III and IV gastric cancer patients.

Changes in the NY-ESO-1 humoral immune responses of the patients during their clinical courses. Serial serum samples were obtained from 25 gastric cancer patients who displayed positive NY-ESO-1 antibody at admission, and the changes in their NY-ESO-1 humoral immune responses were examined throughout their clinical courses. In all, 6 stage I, 2 stage II, and 8 stage III patients received curative surgical treatment, and 14 did not suffer recurrence. The NY-ESO-1 immune response levels of the patients who did not suffer recurrence decreased after treatment and had fallen below the cutoff level by 9 months after surgery in most cases and did not subsequently increase (Figure 1). The half-lives of their NY-ESO-1 humoral immune response levels were 1.5, 1.6, 2.1, 3.2, and 6.6 months in the stage I patients; 3.0 and 4.0 months in the stage II patients; and 1.6, 1.9, 2.3, 3.0, 3.2, 4.1, and 6.7 months in the stage III patients (mean: 3.0 months). On the other hand, the two patients who underwent curative surgery but subsequently suffered recurrence, M-2 (stage I) and M-11 (stage III), displayed not only incomplete decreases in their NY-ESO-1 humoral immune response levels but also their subsequent restoration to pretreatment levels (Figure 1 and Figure 2A and B). In a comparison between the patients' conventional tumour marker levels and their NY-ESO-1 humoral immune response levels, we found that the changes in their CEA and CA19-9 levels were consistent with their NY-ESO-1 immune response levels in patient M-2, whereas patient M-11 was negative for both CEA and CA19-9 throughout their clinical course. Nine stage IV patients who received chemotherapy alone maintained high NY-ESO-1 humoral immune response levels throughout their clinical courses,




Figure 1. Change in the NY-ESO-1 humoral immune responses of gastric cancer patients after treatment. The serum NY-ESO-1 humoral immune responses of patients with stage I, II, III, or IV gastric cancer in whom NY-ESO-1 antibody production was detected before surgical treatment or chemotherapy were serially analysed. In all, 6 stage I, 2 stage II, and 8 stage III patients received curative surgery, and only 2 patients (●, ■) suffered recurrence. Nine patients with stage IV gastric cancer received chemotherapy alone after the initial detection of NY-ESO-1 antibody. Each mark represents a patient. Optical density (OD) values were measured at a serum dilution of 1:200.

including some patients who achieved partial tumour responses after chemotherapy (Figure 1).

Prognostic value of the NY-ESO-1 humoral immune response in gastric cancer. The prognostic value of the NY-ESO-1 immune response was evaluated in gastric cancer patients. An analysis of the cumulative overall survival of the gastric cancer patients indicated that there was no difference in the survival rates of the patients who did and did not display positive NY-ESO-1 humoral immune responses (Figure 3A). However, among the patients with higher stage gastric cancer, overall survival was better in the patients in whom NY-ESO-1 humoral immune responses were

detected, although the difference was not significant (Figure 3B). NY-ESO-1 protein expression, as detected by IHC, did not affect the overall survival rate (data not shown).

DISCUSSION

NY-ESO-1 antibody was detected in 23.2% of stage III and IV gastric cancer patients, and the combinatorial use of the NY-ESO-1

antibody with CEA and CA19-9 as tumour markers increase the percentage of tumour detection from 45.8 to 57.0%. As the frequency of NY-ESO-1 humoral immune response was relatively low in the patients with early-stage gastric cancer, analysing serum NY-ESO-1 antibody levels alone might not be useful for screening for early-stage gastric cancer. Nevertheless, the expression of NY-ESO-1, a CT antigen, is restricted to tumour tissues and NY-ESO-1 antibody is only detectable in patients with NY-ESO-1-expressing tumours (Stockert *et al*, 1998), indicating the highly specific nature of NY-ESO-1 humoral immune responses in cancer patients. Given that NY-ESO-1 expression by malignant cells is required for antibody induction (Stockert *et al*, 1998), the detection of NY-ESO-1 antibody would be helpful for diagnosing malignancy, although extensive analysis of serum samples from patients with non-cancerous disease, for example, liver or renal disorders, autoimmune diseases, and so on, would be necessary to confirm. In our expression analysis, more NY-ESO-1-positive cases were detected by IHC (19 of 60) than by RT-PCR (6 of 60). This was probably due to the heterogeneous expression of NY-ESO-1 in gastric cancer and the fact that a limited number of biopsy samples were used for the RT-PCR, whereas multiple slices from whole tumour specimens were used for the IHC. Extensive IHC analysis should be used for NY-ESO-1 expression studies of gastric cancer.

We detected a correlation between the NY-ESO-1 humoral immune response levels and the clinical outcome after therapy in gastric cancer patients. The patients who underwent surgery and did not suffer a subsequent relapse displayed consistent decreases in their NY-ESO-1 humoral immune response levels or even the complete disappearance of the NY-ESO-1 antibody from their sera. It is generally accepted that constant immunological stimulation is necessary to maintain a strong humoral immune response (Jager *et al*, 1999). Thus, reduction of antigen doses by the removal of NY-ESO-1-expressing tumour is one possible reason for the observed decreases in these patients' NY-ESO-1 humoral immune response levels after surgery. Patients M-2 and M-11, in whom NY-ESO-1 humoral immune responses remained high for 1 year after surgery and increased thereafter, may have a subclinical residual disease of the so-called 'minimal residual cancer' (Austrup *et al*, 2000; Klein *et al*, 2002) after curative surgery. Local recurrent tumours of 23 and 25 mm in diameter subsequently developed in M-2 and M-11, respectively, suggesting that even a small tumour burden is sufficient to stimulate antibody production. Patient M-2 showed a partial decrease in their NY-ESO-1 humoral immune response levels after the resection of the relapsed tumour, and we are carefully observing the progression of this tumour.

Nine patients with stage IV gastric cancer received chemotherapy alone. Among them, six patients displayed stable disease, two




Figure 2. NY-ESO-1 humoral immune response, CEA, and carbohydrate antigen (CA)19-9 levels of patients who relapsed after curative surgery. The NY-ESO-1 humoral immune response (●, ■; Figure 1), CEA, and CA19-9 levels of two patients, M-2 (stage I) (A) and M-11 (stage III) (B), who underwent curative surgery but subsequently suffered recurrence, were serially analysed. OD values were measured at a serum dilution of 1:200. The closed marks indicate CEA or CA19-9 positivity.




Figure 3. Prognostic role of NY-ESO-1 antibody in gastric cancer patients. The cumulative overall survival rate was analysed in all patients (n=310; A) and stage III and IV (n=126; B) gastric cancer patients in whom NY-ESO-1 antibodies were (continuous line) and were not detected (dotted line). The detection of NY-ESO-1 protein by IHC analysis did not affect the overall survival rate (data not shown). Survival curves were plotted using the Kaplan-Meier method. The log-rank test was used for comparisons between groups. P-values <0.05 were considered significant.

patients displayed progressive disease, and one patient (M-19) achieved a partial response. Serial analysis of the NY-ESO-1 humoral immune responses of these nine patients including M-19 showed that they barely changed throughout their clinical courses, suggesting that even small tumours are enough to provoke strong NY-ESO-1 humoral immune responses. In this regard, the NY-ESO-1 humoral immune response might not be suitable as a clinical marker for palliative therapy.

We have performed serial cancer vaccine clinical trials with NY-ESO-1 because of its strong immunogenicity and high specificity (Uenaka *et al*, 2007; Wada *et al*, 2008; Kakimi *et al*, 2011). The NY-ESO-1 humoral immune response could be a reliable marker of the induction of immune response, as well as for predicting clinical responses in these trials. Furthermore, antibody-based examinations detected both intra- and intermolecular antigen spreading in the sera of patients who had been vaccinated with NY-ESO-1 protein (Kawada *et al*, 2012), suggesting the possible correlation of NY-ESO-1 humoral immune responses and clinical status. In addition, we have started a phase I study of vaccination with NY-ESO-1 protein mixed with Hiltonol (Poly ICLC), Picibanil (OK-432), and Montanide (ISA-51) in patients with NY-ESO-1-expressing cancers (UMIN000007954). Furthermore, NY-ESO-1 vaccine involving modulators of immune checkpoints, for example, anti-CTLA4 antibody and anti-PD-1 antibody, and reagents that are antagonistic to regulatory T cells, for example, anti-CCR4 antibody (Pardoll, 2012) should be considered.

Recently, the antibody against p53, another tumour antigen, has been recognised as a useful tumour marker (Lubin *et al*, 1995). Shimada *et al* (2000) reported that p53 antibody was detected in 35% of serum samples from patients with *in situ* oesophageal cancer and that it disappeared after endoscopic mucosal resection, proposing that p53 antibody is useful for the early detection and subsequent monitoring of oesophageal cancer. In addition, Müller *et al* (2006) reported that p53 antibody was found in 23.4% of serum samples from cancer patients with 100% accuracy and was correlated with poor prognosis in hepatocellular carcinoma and breast cancer.

Here, we have demonstrated that the NY-ESO-1 humoral immune response could also be valuable as a marker for detecting advanced gastric cancer and inferring whether residual tumour cells remain after treatment, although its frequency in gastric cancer is not very high. We have started a prospective multi-institutional clinical study of NY-ESO-1 humoral immune responses in higher stage gastric cancer patients. In this new study, the NY-ESO-1 humoral immune responses of approximately 100 patients who relapsed after curative surgery will be serially analysed and then followed up. This trial has been registered as UMIN000007925 in Japan.

ACKNOWLEDGEMENTS

We thank Dr Lloyd J Old for his continuous encouragement and Dr K Kakimi for critically reviewing this manuscript.

REFERENCES

- Alexander JC, Silverman NA, Chretien PB (1976) Effect of age and cigarette smoking on carcinoembryonic antigen levels. *JAMA* **235**: 1975–1979.
- Austrup F, Uciechowski P, Eder C, Böckmann B, Suchy B, Driesel G, Jäckel S, Kusiak I, Grill HJ, Giesing M (2000) Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. *Br J Cancer* **83**: 1664–1673.
- Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. *Ann Oncol* **18**: 868–873.
- Ferro MA, Barnes I, Roberts JB, Smith PJ (1987) Tumor markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. *Br J Urol* **60**: 69–73.
- Fujiyama S, Morishita T, Sagara K, Sato T, Motohara K, Matsuda I (1986) Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. *Hepatogastroenterology* **33**: 201–205.
- Gati A, Lajmi N, Derouiche A, Marrakchi R, Chebil M, Benammar-Elgaaied A (2011) NY-ESO-1 expression and immunogenicity in prostate cancer patients. *Tunis Med* **89**: 779–783.
- Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT, Old LJ (2006) NY-ESO-1: review of an immunogenic tumor antigen. *Adv Cancer Res* **95**: 1–30.
- Graziosi L, Bugiantella W, Cavazzoni E, Cantarella F, Porcari M, Baffa N, Donini A (2011) Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour. *Ann Ital Chir* **82**: 125–129.
- Ikeda Y, Mori M, Adachi Y, Matsushima T, Sugimachi K, Saku M (1993) Carcinoembryonic antigen (CEA) in stage IV gastric cancer as a risk factor for liver metastasis: a univariate and multivariate analysis. *J Surg Oncol* **53**: 235–238.
- Isobe M, Eikawa S, Uenaka A, Nakamura Y, Kanda T, Kohno S, Kuzushima K, Nakayama E (2009) Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient. *Cancer Immun* **9**: 8.
- Jäger E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jäger D, Arand M, Ritter G, Old LJ, Knuth A (1999) Humoral immune responses of cancer patients against 'Cancer-Testis' antigen NY-ESO-1: correlation with clinical events. *Int J Cancer* **84**: 506–510.
- Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraiishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E (2011) A phase I study of vaccination with NY-ESO-1 peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. *Int J Cancer* **129**: 2836–2846.
- Katanoda K, Yako-Suketomo H (2009) Comparison of time trends in stomach cancer incidence (1973–2002) in Asia, from Cancer Incidence in Five Continents, Vols IV–IX. *Jpn J Clin Oncol* **39**: 71–72.
- Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, Okazaki N, Uenaka A, Nakamura Y, Fujiwara S, Mizuno N, Saika T, Ritter E, Yamasaki M, Miyata H, Ritter G, Murphy R, Venhaus R, Pan L, Old LJ, Doki Y, Nakayama E (2012) Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. *Int J Cancer* **130**: 584–592.
- Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmüller G (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. *Lancet* **360**: 683–689.
- Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T (1996) The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. *Am J Gastroenterol* **91**: 49–53.
- Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP (1995) P53 antibodies in patients with various types of cancer: assay, identification, and characterization. *Clin Cancer Res* **1**: 1463–1469.
- Makino T, Fujiwara Y, Takiguchi S, Miyata H, Yamasaki M, Nakajima K, Nishida T, Mori M, Doki Y (2010) The utility of pre-operative peritoneal lavage examination in serosa-invading gastric cancer patients. *Surgery* **148**: 96–102.
- Motoori M, Takemasa I, Doki Y, Saito S, Miyata H, Takiguchi S, Fujiwara Y, Yasuda T, Yano M, Kurokawa Y, Komori T, Yamasaki M, Ueno N, Oba S, Ishii S, Monden M, Kato K (2006) Prediction of peritoneal metastasis in advanced gastric cancer by gene expression profiling of the primary site. *Eur J Cancer* **42**: 1897–1903.
- Müller M, Meyer M, Schilling T, Ulsperger E, Lehnert T, Zentgraf H, Stremmel W, Volkman M, Galle PR (2006) Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. *Int J Oncol* **29**: 973–980.
- Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, Nasu Y, Tsushima T, Kumon H, Old LJ, Nakayama E (2003) NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. *Cancer Immunol* **3**: 10.
- Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* **12**: 252–264.

- Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. *J Clin Oncol* **29**: 4387–4393.
- Seamonds B, Yang N, Anderson K, Whitaker B, Shaw LM, Bollinger JR (1986) Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. *Urology* **28**: 472–479.
- Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. *Cancer* **89**: 1677–1683.
- Statistics and Information Department (2006) *Ministry of Health, Labour, and Welfare Vital Statistics of Japan 2004*. Health and Welfare Statistics Association: Tokyo.
- Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. *J Exp Med* **187**: 1349–1354.
- Takahashi Y, Mai M, Kusama S (1998) Factors influencing growth rate of recurrent stomach cancer as determined by analysis of serum carcinoembryonic antigen. *Cancer* **75**: 1497–1502.
- Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H (2003) The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. *Gastric Cancer* **6**: 142–145.
- Türeci O, Mack U, Luxemburger U, Heinen H, Krummenauer F, Sester M, Sester U, Sybrecht GW, Sahin U (2006) Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. *Cancer Lett* **236**: 64–71.
- Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E (2007) T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. *Cancer Immun* **7**: 9.
- Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, Iwae S, Yonezawa K, Yamasaki M, Miyata H, Doki Y, Shiku H, Jungbluth AA, Ritter G, Murphy R, Hoffman EW, Old LJ, Monden M, Nakayama E (2008) Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. *Int J Cancer* **123**: 2362–2369.
- Yamamoto M, Baba H, Kakeji Y, Endo K, Ikeda Y, Toh Y, Kohnoe S, Okamura T, Maehara Y (2004) Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer. *Oncology* **67**: 19–26.
- Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. *Proc Natl Acad Sci USA* **108**: 16723–16728.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.



Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial

Toshimasa Tsujinaka, Kazuyoshi Yamamoto, Junya Fujita, Shunji Endo, Junji Kawada, Shin Nakahira, Toshio Shimokawa, Shogo Kobayashi, Makoto Yamasaki, Yusuke Akamaru, Atsushi Miyamoto, Tsunekazu Mizushima, Junzo Shimizu, Koji Umeshita, Toshinori Ito, Yuichiro Doki, Masaki Mori, for the Clinical Study Group of Osaka University on Section of Risk Management

Summary

Background Staples have been widely used for skin closure after open gastrointestinal surgery. The potential advantages of subcuticular sutures compared with staples have not been assessed. We assessed the differences in the frequency of wound complications, including superficial incisional surgical site infection and hypertrophic scar formation, depending on whether subcuticular sutures or staples are used.

Methods We did a multicentre, open-label, randomised controlled trial at 24 institutions between June 1, 2009, and Feb 28, 2012. Eligible patients aged 20 years or older, with adequate organ function and undergoing elective open upper or lower gastrointestinal surgery, were randomly assigned preoperatively to either staples or subcuticular sutures for skin closure. Randomisation was done via a computer-generated permuted-block sequence, and was stratified by institution, sex, and type of surgery (ie, upper or lower gastrointestinal surgery). Our primary endpoint was the incidence of wound complications within 30 days of surgery. Analysis was done by intention to treat. This study is registered with UMIN-CTR, UMIN000002480.

Findings 1080 patients were enrolled and randomly assigned in a one to one ratio: 562 to subcuticular sutures and 518 to staples. 1072 were eligible for the primary endpoint and 1058 for the secondary endpoint. Of the 558 patients who received subcuticular sutures, 382 underwent upper gastrointestinal surgery and 176 underwent lower gastrointestinal surgery. Wound complications occurred in 47 of 558 patients (8·4%, 95% CI 6·3–11·0). Of the 514 who received staples, 413 underwent upper gastrointestinal surgery and 101 underwent lower gastrointestinal surgery. Wound complications occurred in 59 of 514 (11·5%, 95% CI 8·9–14·6). Overall, the rate of wound complications did not differ significantly between the subcuticular sutures and staples groups (odds ratio 0·709, 95% CI 0·474–1·062; $p=0\cdot12$).

Interpretation The efficacy of subcuticular sutures was not validated as an improvement over a standard procedure for skin closure to reduce the incidence of wound complications after open gastrointestinal surgery.

Funding Johnson & Johnson.

Introduction

Wound complications are among the most common issues reported after surgery, and are often very problematic for patients in terms of cosmetic appearance, decreased quality of life, prolonged hospital stays, and increased health-care costs.^{1,2} Several publications have addressed ways to reduce the risk of wound complications associated with surgery,^{3–6} such as intraoperative administration of antimicrobial prophylaxis,^{4,5} skin preparation, barrier retraction wound protection,⁷ use of absorbable sutures during intraperitoneal procedures,^{8,9} and pulsatile lavage irrigation of wounds before closure.^{10,11} Triclosan-coated sutures significantly reduced the rate of surgical site infections compared with conventional uncoated sutures in various types of surgery.¹²

Because of the increase in the number of patients with preoperative comorbidities that are risk factors for wound complications, such as malnutrition,¹³ diabetes mellitus,¹⁴ and obesity,¹⁵ new, innovative approaches will be necessary to decrease the risk of wound complications after surgery.

Subcuticular suturing for skin closure is an attractive alternative for skin approximation in most types of surgery. It is often used in plastic surgery because of the low incidence of wound complications and good cosmetic appearance.^{16–18} Compared with staples, several clinical trials have shown that subcuticular sutures are associated with a significantly lower incidence of wound complications and better cosmetic results after orthopaedic surgery,¹⁹ cardiovascular surgery,^{20,21} and caesarean section.^{22,23}

In 242 patients undergoing coronary artery bypass graft surgery, Johnson and colleagues²⁴ prospectively closed half of each sternal and saphenous vein harvest wound with staples and half with intradermal sutures. The incidence of wound infection was similar with both methods, but significantly fewer wound complications were noted with subcuticular sutures than with staples. Additionally, patients who expressed a preference preferred sutures to staples. Basha and investigators²⁵ randomly assigned 435 patients undergoing caesarean delivery to stainless steel staples or subcuticular 4·0 monocril sutures. They

Lancet 2013; 382: 1105–12

See Comment page 1076

Department of Surgery, Kaizuka City Hospital, Osaka, Japan (T Tsujinaka MD); Department of Surgery, National Hospital Organisation Osaka National Hospital, Osaka, Japan (K Yamamoto MD, A Miyamoto MD); Department of Surgery, NTT West Osaka Hospital, Osaka, Japan (J Fujita MD); Department of Surgery, Higashiosaka City General Hospital, Osaka, Japan (S Endo MD); Department of Surgery, Osaka General Medical Centre, Osaka, Japan (J Kawada MD); Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan (S Nakahira MD); Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan (T Shimokawa PhD); Department of Gastroenterological Surgery (S Kobayashi MD, M Yamasaki MD, T Mizushima MD, Prof K Umeshita MD, Prof T Ito MD, Prof Y Doki MD, Prof M Mori MD), and Department of Complementary and Alternative Medicine (Prof T Ito), Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Surgery, Osaka-Koseinenkin-Hospital, Osaka, Japan (Y Akamaru MD); and Department of Surgery, Osaka Rosai Hospital, Osaka, Japan (J Shimizu MD)

Correspondence to: Dr Toshimasa Tsujinaka, Department of Surgery, Kaizuka City Hospital, 3-10-20 Hori, Kaizuka, 597-0015 Osaka, Japan tsujinaka@hosp.kaizuka.osaka.jp

reported that staple closure was associated with a four-times increased risk of wound separation (adjusted odds ratio [OR] 4.66, 95% CI 2.07–10.52; $p < 0.001$) and poor patient satisfaction.

These trials had been done for class 1 surgical procedures—ie, clean surgery. However, the benefit of subcuticular sutures in gastrointestinal surgery, a class 2 (clean-contaminated) surgery that is associated with a high incidence of wound complications,^{15,26,27} has not been fully examined.²⁸ Staples are the most commonly used technique for skin closure during gastrointestinal surgery because of convenience and speed. Because no consensus has been reached about how to apply findings from class 1 surgery to class 2 surgery, an optimum method of skin for gastrointestinal surgery remains to be established.

We investigated differences in prevention of wound complications between subcuticular sutures and staples after elective upper and lower gastrointestinal open surgery.

Methods

Study design and participants

We did a large-scale, multicentre, open-label, phase 3 randomised controlled trial at 24 institutions in Japan from June 1, 2009, to Feb 28, 2012. The study was organised by the Clinical Study Group of Osaka University on Risk Management (OSGO-RM), which is composed of hospitals affiliated from the Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University.

Eligible patients were undergoing elective upper or lower gastrointestinal surgery, aged 20 years or older, and had adequate organ function. Patients undergoing abdominoperineal resection for rectal cancer were also eligible, but we only assessed abdominal wounds for outcomes. We excluded patients needing emergency or laparoscopic surgery, with a history of laparotomy with a midline incision, or with long-term corticosteroid use; active infection such as peritonitis, pneumonia, or urinary tract infection; massive ascites; coagulopathy or other disorders that would preclude study participation; uncontrolled or insulin-treated diabetes; mental illness, poor general condition; severe cardiopulmonary disease; or who were deemed by surgeons to be inappropriate for participation in a randomised trial. The institutional review board of each hospital approved the protocol. All patients provided written informed consent before randomisation. We did not collect data on the number of patients approached and assessed for eligibility.

Randomisation and masking

Patients were recruited by the investigators and treatment allocation was made preoperatively after confirming eligibility.

Enrolment was done through a web-based system established for this trial and randomisation by a computer-generated permuted-block sequence. The size of

the blocks used for randomisation was four. Patients were randomly assigned (1:1) to either subcuticular sutures or staples for skin closure and balanced according to institution, sex, and type of surgery (ie, upper or lower gastrointestinal open surgery). Investigator surgeons were informed of the treatment allocation via the internet and did the procedures. Patients and investigators were not masked to group assignment. The data centre, based at the Multicenter Clinical Study Group at Osaka University was responsible for treatment allocation, central monitoring, and statistical analyses under the supervision of the statistician in charge.

Procedures

In the subcuticular suture group, surgeons used interrupted subcuticular sutures with 3-0 or 4-0 monofilament absorbable suture (polydioxanone; PDS-II Ethicon, Tokyo, Japan). The interval of the subcuticular sutures was 15–25 mm and the length of the bite of sutures was 15–25 mm from the edge of the skin. Under this condition, the skin could be closed tightly. Use of sterile strips or skin glue for epidermal approximation in addition to subcuticular sutures was an institutional choice. In the staples group, metallic skin staples, which were the choice of individual institutions, 10–15 mm apart were used. Approximation of the fat layer was not allowed in the either group. Before the trial, investigators from participating institutions were instructed on how to do subcuticular sutures during the trial. A video in which a plastic surgeon used the subcuticular suturing technique (adopted as the standard) was provided to each participating institution. The standard procedure was also demonstrated at each investigator meeting. Investigators and physicians in training met yearly to examine how subcuticular sutures were done.

All participating institutions were asked to follow the guidelines about prevention of surgical site infections issued by the US Centers for Disease Control and Prevention (CDC).²⁹ Surgical gloves and instruments were changed before wound closure. Absorbable monofilament sutures were used for approximation of the fascia, and the subcutaneous space was irrigated with saline without added antibiotics. Intra-abdominal drain placement through a separate incision away from the operative incision was permitted but drainage of the wound was not allowed. Skin preparation techniques, prophylactic antibiotic administration, the volume of saline used for intra-abdominal irrigation, dressing methods, and timing of postoperative staple removal, perioperative care, and wound management were according to each participating institution's respective standards.

Our primary outcome was incidence of wound complications within 30 days of surgery. The secondary outcome was the incidence of hypertrophic scar formation 6 months after surgery. Wound complications were defined as the presence of at least one of several signs or symptoms necessitating treatment: wound disruption,

stitch abscess, abscess caused by metal allergy, seroma or haematoma, or superficial incisional surgical site infections. Superficial incisional surgical site infections are defined by the CDC²⁹ as infections occurring within 30 days of surgery that implicate only the skin or subcutaneous tissue of the incision. Diagnosis of superficial incisional surgical site infection must satisfy one or more of several criteria: purulent drainage (with or without laboratory confirmation) from the superficial incision, organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision, or at least one of the signs or symptoms of infection (pain or tenderness, localised swelling, redness or heat, and superficial incision deliberately opened by the surgeon, unless the incision is culture-negative). Infection control personnel monitored and detected surgical site infections during patients' hospital stays. Changes noted in the wound were not defined as wound complications if they did not necessitate treatment. When superficial incisional surgical site infections and other wound complications coexisted in the same patient, we defined the complication as superficial incisional surgical site infections. We defined hypertrophic scar as a widened or elevated unsightly scar with erythema or pigmentation.

Responsible surgeons checked for the presence or absence of wound complications every day during the hospital stay and at every outpatient visit until 30 days after surgery. They were also responsible for checking for the presence or absence of hypertrophic scar formation at 6 months after surgery, and measured the width and length of detected hypertrophic scars. Before starting the trial, the principal investigator showed typical cases of various wound complications and hypertrophic scars, and consensus about all types of wound complications was reached by the investigators.

Statistical analysis

We planned a sample size of 530 patients per treatment group when we designed the trial. Such a sample size would provide power of 80% with a two-sided significance level of 0.05 to detect superiority in the reduction of the frequency of wound complications. Wound complications were anticipated in 11% of patients in the staples group and 6% in the subcuticular sutures group, allowing for a loss to follow-up of roughly 10%. The projected accrual period was 2 years and no interim analyses were planned.

We did the analysis on a modified intention-to-treat basis. We expressed continuous numerical data as medians and IQRs or means and SDs, when appropriate, and distribution of dichotomous data in percentages with 95% CIs. We used Fisher's exact test to compare binary variables and the Mann-Whitney *U* test to compare continuous variables. All *p* values of less than 0.05 were deemed significant.

The primary outcome was analysed with Fisher's exact test, and we used the Mantel-Haenszel test to adjust for the type of surgery, a potential confounding factor, which was

not prespecified in the protocol. We used Fisher's exact test to analyse the secondary outcome and to calculate and compare outcomes as a post-hoc analysis on the basis of type of surgery.

We analysed thickness of subcutaneous fat (objectively classified by the surgeon as either thin, normal, or thick), American Society of Anesthesiologists (ASA) physical status classification,³⁰ operative time, intraoperative blood loss volume, duration of prophylactic antibiotics, presence of drainage tube and duration of drainage, and use of postoperative anticoagulant therapy as variables. Subgroups were analysed with logistic regression to assess for statistical interactions between treatments in various subgroups. Because of the exploratory nature of subgroup comparisons, we report test results without multiplicity adjustments for type I error. This study is registered with UMIN-CTR, UMIN000002480. UMIN-CTR is one of the network members of the Japan Primary Registries Network, which meets WHO registry criteria.

Role of the funding source

The sponsor had no roles in the study design; data collection, analysis, or interpretation; or writing of the Article. The corresponding author had full access to all




Figure 1: Trial profile

	Subcuticular sutures (n=562)	Staples (n=518)
Age (years)	68 (61-75)	68 (61-74)
Sex		
Male	388 (69.0%)	365 (70.5%)
Female	174 (31.0%)	153 (29.5%)
Surgery		
Upper gastrointestinal	385 (68.5%)	417 (80.5%)
Lower gastrointestinal	177 (31.5%)	101 (19.5%)
Thickness of subcutaneous fat*		
Thick	143 (25.6%)	109 (21.2%)
Standard	328 (58.8%)	317 (61.6%)
Thin	87 (15.6%)	89 (17.3%)
ASA physical status classification*		
1	201 (36.0%)	201 (39.0%)
2	313 (56.1%)	273 (53.0%)
3	44 (7.9%)	41 (8.0%)
Operative time (min)*	228 (180-270)	218 (175-264)
Blood loss (mL)	230 (100-430)	244 (120-450)
Wound protection†		
Surgical drape	535 (95.9%)	497 (96.3%)
Gauze	10 (1.8%)	6 (1.2%)
None	13 (2.3%)	13 (2.5%)
Duration of antibiotic prophylaxis (days)*		
1	379 (67.9%)	373 (72.4%)
2	33 (5.9%)	22 (4.3%)
3	100 (17.9%)	86 (16.7%)
≥4	46 (8.2%)	34 (6.6%)
Duration of drain insertion (days)*		
0 (ie, no drain)	118 (21.1%)	108 (21.0%)
1-3	50 (9.0%)	34 (6.6%)
≥4	390 (69.9%)	373 (72.4%)
Duration of hospital stay after surgery (days)	14 (11-21)	15 (12-21)
Anticoagulation therapy‡		
Yes	130 (23.3%)	96 (18.6%)
No	429 (76.7%)	420 (81.4%)

Data are n (%) or median (IQR). ASA=American Society of Anesthesiologists.³⁰
 *Data missing for four patients in the subcuticular sutures group and three patients in the staples group. †Data missing for four patients in the subcuticular sutures group and two patients in the staples group. ‡Data missing for three patients in the subcuticular sutures group and two patients in the staples group.

Table 1: Baseline demographic and clinical characteristics

the data and was responsible for the decision to submit for publication.

Results

Figure 1 shows the trial profile. 1080 patients from 24 institutions were enrolled and randomly assigned—562 to subcuticular sutures and 518 to staples. Assessment of case report forms showed that four patients in each group were ineligible for inclusion, and thus the modified intention-to-treat population comprised 558 patients in the subcuticular sutures group and 514 in the staples group

	Subcuticular sutures (n=385)	Staples (n=417)
Diseases		
Gastric cancer	375 (97.4%)	403 (96.6%)
Gastric submucosal tumour	6 (1.6%)	9 (2.2%)
Other	4 (1.0%)	5 (1.2%)
Procedures		
Total gastrectomy	149 (38.7%)	143 (34.3%)
Distal gastrectomy	186 (48.3%)	219 (52.5%)
Proximal gastrectomy	19 (4.9%)	16 (3.8%)
Exploratory laparotomy	4 (1.0%)	4 (1.0%)
Other	27 (7.0%)	35 (8.4%)

Data are n (%).

Table 2: Types of diseases and surgical procedures in patients undergoing upper gastrointestinal surgery

	Subcuticular sutures (n=177)	Staples (n=101)
Diseases		
Colon cancer	98 (55.4%)	51 (50.5%)
Rectal cancer	71 (40.1%)	48 (47.5%)
Anal cancer	2 (1.1%)	1 (1.0%)
Other	6 (3.4%)	1 (1.0%)
Procedures		
Right hemicolectomy	41 (23.2%)	28 (27.7%)
Left hemicolectomy	44 (24.9%)	8 (7.9%)
Low anterior resection	61 (34.5%)	38 (37.6%)
Abdominoperineal resection	11 (6.2%)	10 (9.9%)
Partial resection of colon	9 (5.1%)	10 (9.9%)
Other	11 (6.2%)	7 (6.9%)

Data are n (%).

Table 3: Types of diseases and surgical procedures in patients undergoing lower gastrointestinal surgery

(figure 1). Ten patients in the subcuticular sutures group and three in the staples group needed reoperation within 30 days, which met the exclusion criterion, a history of laparotomy, and thus were not assessed for wound complications.

Distribution of most demographic and clinical characteristics of enrolled patients was balanced between groups except type of surgery (table 1). Tables 2 and 3 show details of the diseases and surgical procedures in the two groups. 417 patients who underwent upper gastrointestinal surgery were allocated to the staples group and 385 to the subcuticular sutures group, and 177 patients who underwent lower gastrointestinal surgery were allocated to the subcuticular sutures group and 101 to the staples group.

In the subcuticular sutures group, wound complications occurred in 47 of 558 (8.4%, 95% CI 6.3-11.0) patients, including 36 (6.4%, 4.6-8.8) patients with superficial incisional surgical site infections. In the staples group, wound complications occurred in 59 of 514 patients

	All patients				Upper gastrointestinal surgery				Lower gastrointestinal surgery			
	Subcuticular suture (n=558)	Staples (n=514)	Odds ratio (95% CI)	p	Subcuticular sutures (n=382)	Staples (n=413)	Odds ratio (95% CI)	p	Subcuticular sutures (n=176)	Staples (n=101)	Odds ratio (95% CI)	p
Primary outcome												
Wound complication rate*	47 (8.4%)	59 (11.5%)	0.709 (0.474-1.062)	0.12	29 (7.6%)	39 (9.4%)	0.788 (0.459-1.339)	0.38	18 (10.2%)	20 (19.8%)	0.463 (0.217-0.978)	0.0301
Component outcomes												
Surgical site infection (superficial incisional)	36 (6.4%)	36 (7.0%)	0.928 (0.558-1.543)	0.81	23 (6.0%)	20 (4.8%)	1.259 (0.649-2.461)	0.53	13 (7.4%)	16 (15.8%)	0.425 (0.179-0.992)	0.0399
Non-surgical-site infection	11 (2.0%)	23 (4.5%)	0.435 (0.189-0.940)	0.0238	6 (1.6%)	19 (4.6%)	0.331 (0.107-0.875)	0.0149	5 (2.8%)	4 (4.0%)	0.710 (0.149-3.666)	0.73
Wound separation	3 (0.5%)	8 (1.6%)	0.346 (0.059-1.453)	0.13	1 (0.3%)	6 (1.5%)	0.178 (0.004-1.480)	0.13	2 (1.1%)	2 (2.0%)	0.570 (0.041-7.979)	0.62
Seroma	5 (0.9%)	12 (2.3%)	0.383 (0.105-1.179)	0.09	3 (0.8%)	11 (2.7%)	0.290 (0.052-1.108)	0.06	2 (1.1%)	1 (1.0%)	1.149 (0.059-68.457)	1.00
Haematoma	1 (0.2%)	2 (0.4%)	0.466 (0.008-8.969)	0.61	0 (0.0%)	1 (0.2%)	1 (0.6%)	1 (1.0%)	0.573 (0.007-45.300)	1.00
Other	2 (0.4%)	1 (0.2%)	1.867 (0.097-110.358)	1.00	2 (0.5%)	1 (0.2%)	2.166 (0.112-128.141)	0.61	0 (0.0%)	0 (0.0%)

Significance was calculated with Fisher's exact test. *Adjusted odds ratio 0.658 (95% CI 0.438-0.988; p=0.0438 [calculated with Mantel-Haenszel test]).

Table 4: Primary outcome and its components in modified intention-to-treat population

(11.5%, 8.9-14.6), including 36 (7.0%, 5.0-9.6) with superficial incisional surgical site infections (table 4). As a primary outcome, the number of wound complications did not differ significantly between the two groups (OR 0.709, 95% CI 0.474-1.062; p=0.12). Since we identified confounding with the stratified factor, type of surgery, adjustment was done to show a significant difference (0.658, 0.438-0.988; p=0.0438), although this was not prespecified.

Post-hoc exploratory analyses showed that wound complications excepting surgical site infections occurred significantly less often in the subcuticular suture group than in the staples group overall (OR 0.435, 95% CI 0.189-0.940; p=0.0238) and in patients who underwent upper gastrointestinal surgery (0.331, 0.107-0.875; p=0.0149). In patients who underwent lower gastrointestinal surgery, significantly fewer wound complications (0.463, 0.217-0.978; p=0.0301) and superficial incisional surgical site infections (0.425, 0.179-0.992; p=0.0399) were noted in the subcuticular sutures than in the staples group (table 4).

Table 5 summarises secondary outcomes. Significantly fewer hypertrophic scars formed in the subcuticular sutures group than in the staples group overall (OR 0.726, 0.528-0.998; p=0.0429) and specifically in patients who underwent upper gastrointestinal surgery (0.672, 0.465-0.965; 0.0282).

We did a post-hoc subset analysis to identify potential interactions between wound complications and background factors (figure 2). Significant risk reduction for wound complications was noted with subcuticular sutures compared with staples in male patients (vs female patients), lower gastrointestinal surgery (vs upper gastrointestinal

	n	Hypertrophic scar formation	Odds ratio (95% CI)	p
All patients			0.726 (0.528-0.998)	0.0429
Subcuticular sutures	558	93 (16.7%)		
Staples	514	111 (21.6%)		
Upper gastrointestinal surgery			0.672 (0.465-0.965)	0.0282
Subcuticular sutures	382	66 (17.3%)		
Staples	413	98 (23.7%)		
Lower gastrointestinal surgery			1.226 (0.576-2.729)	0.72
Subcuticular sutures	176	27 (15.3%)		
Staples	101	13 (12.9%)		

Data for hypertrophic scar formation are n (%). Significance was calculated with Fisher's exact test.

Table 5: Secondary outcomes in the modified intention-to-treat population

surgery), cases with operative time of 220 min or greater (vs those with operative times <220 min), and patients receiving postoperative anticoagulant therapy (vs those not receiving such therapy). We did not identify any important treatment-related adverse events for stapling or subcuticular sutures.

Discussion

Subcuticular sutures for skin closure have been advocated instead of staples in clean (class 1) surgery, including cardiovascular surgery,²⁴ orthopaedic surgery,¹⁹ and caesarean delivery,²⁵ on the basis of the results of randomised studies. Whether these results can be applied to class 2 surgery, as represented by gastrointestinal surgery, is of concern. Classification of the types of surgery is described in panel 1. Our results show that subcuticular sutures did not significantly reduce the frequency of




Figure 2: Subset analysis of wound complications in the modified intention-to-treat population. Significance was calculated with Fisher's exact test. ASA=American Society of Anesthesiologists.

wound complications as a primary outcome and therefore subcuticular sutures are not validated as a new standard procedure for skin closure after gastrointestinal surgery (panel 2). As a secondary outcome, we noted fewer hypertrophic scars formed when subcuticular sutures were used than when staples were used.

Our sample size calculation was done on the assumption that the incidence of wound complications was 7.5% with upper gastrointestinal surgery and 15% with lower gastrointestinal surgery when staples were used and the expected number of patients receiving the respective surgery was equal (1:1), which gave the incidence of wound complications as 11%. We postulated that a 5% reduction of the incidence of wound complications by subcuticular sutures was necessary to be a new standard procedure for skin closure. There are several reasons why we did not obtain the results we expected. We showed that the incidences of wound complications were 8.4% in the subcuticular sutures group and 11.5% in the

Panel 1: Classification of types of surgery (class 1 and 2)²⁹

Class 1 (clean)

An uninfected operative wound in which no inflammation is encountered and the respiratory, alimentary, genital, or uninfected urinary tract is not entered. For example, skin procedures (ie, biopsies), simple orthopaedic surgery, vascular surgery, and elective caesarean section.

Class 2 (clean-contaminated)

An operative wound in which the respiratory, alimentary, genital, or urinary tracts are entered under controlled conditions and without unusual contamination. For example, gastrointestinal surgery, thoracic procedures, gynaecological procedures, and emergency caesarean section.

staples group ($p=0.12$) in all patients, 7.6% and 9.4% ($p=0.38$) in upper gastrointestinal surgery, and 10.2% and 19.8% ($p=0.0301$) in lower gastrointestinal surgery (table 4). Subcuticular sutures were more effective in lower gastrointestinal surgery, whereas enrolment of patients receiving open lower gastrointestinal surgery was substantially lower than that of patients receiving open upper gastrointestinal surgery (278 vs 802) because laparoscopic surgery has become more prevalent in lower gastrointestinal surgery. Although we included type of surgery as one of our stratification variables, more patients who underwent lower gastrointestinal surgery received subcuticular sutures than staples (177 vs 101) and more patients who underwent upper gastrointestinal surgery received staples than subcuticular sutures (417 vs 385) as a result of the unexpected unbalanced allocation (tables 2, 3), which might be caused by participation of many institutions and the presence of three stratification factors. These factors attenuated the postulated effect of subcuticular sutures and the analysis of the primary outcome did not reach significance. When adjusting for the type of surgery, subcuticular sutures seemed to confer a benefit, although this result is not conclusive. Thus, preferential use of subcuticular sutures might be supported in some circumstances. Although we did not analyse outcomes of individual institutions, there was possibility of heterogeneity with regard to the effect of subcuticular sutures caused by as many as 24 institutions.

Before this trial, few data for potential differences in the rate of wound complications and hypertrophic scar formation between upper and lower gastrointestinal surgery were available. That the incidence of superficial incisional surgical site infections was higher with lower gastrointestinal surgery than with upper gastrointestinal surgery had been previously reported,¹⁵ which was the reason why we used type of surgery as a stratification factor. We showed that the incidence of total wound complications and superficial incisional surgical site infections was significantly higher in lower than in upper gastrointestinal surgery, whereas the incidence of

hypertrophic scar formation was higher in upper than in lower gastrointestinal surgery. Subcuticular sutures reduced the incidence of wound complications compared with staples in lower gastrointestinal surgery and the formation of hypertrophic scars in upper gastrointestinal surgery, possibly because of the higher number of events of those types in these types of surgery, respectively.

Subset analysis showed that subcuticular sutures resulted in significantly fewer wound complications in some subgroups, such as lower gastrointestinal surgery, longer operative time, and postoperative anticoagulant therapy, and the frequency of wound complications in almost all subsets of patients was lower in the subcuticular sutures group than in the staples group.

It is reasonable to employ subcuticular sutures in other types of gastrointestinal surgery, especially hepatobiliary or pancreatic surgery, which exert extensive surgical stress and are associated with large volumes of blood loss, long operative times, and a high incidence of surgical site infections.^{41,42} We did not include hepatobiliary or pancreatic surgery in this trial because they contain a wide variety of surgical procedures and different levels of surgical site infection rates. The results of our subset analysis imply that subcuticular sutures could be applied to other types of gastrointestinal surgery and might reduce wound complications.⁴³

We persuaded investigators to follow the US national surgical infection prevention guidelines, which recommend that antibiotic prophylaxis should be discontinued within 24 h of surgery.⁴ As a result, 67.9% in the subcuticular sutures group and 72.4% in the staples group received prophylaxis with antibiotics for 1 day in this trial. Compared with the result of a national cohort study in the USA,⁴⁴ reporting that about 60% of patients who had major surgery were still receiving antimicrobial prophylaxis at 24 h after surgery, our results were acceptable. We did not find an imbalance between the groups.

Our study had several limitations. First, the absence of masking could have biased the detection of wound complications. However, assessment of surgical site infections was done by infection control personnel at the participating institutions who did not have roles in trial design or conduct. Detection of other wound complications was based on whether some treatment (dressing or surgical intervention) for wound management was documented in the medical record, which could minimise bias. However, it was possible that the open nature of our trial might have affected the findings. The Japanese insurance system and common clinical practice permitted examination of patients by responsible surgeons at outpatient clinics 1 month and 6 months after surgery, which allowed for accurate assessment of the wound even though allocation was not masked.

Second, it has been reported that subcuticular sutures for skin closure have advantages compared with staples with regard to cosmetic considerations,^{16–18} patient

Panel 2: Research in context

Systematic review

We searched Medline and the Cochrane Database of Systematic Reviews with the terms “subcuticular suture, cutaneous closure, or dermal closure”, “staple or staple closure”, and “randomised controlled trial or phase 3 trial”. We identified 11 randomised trials: four for caesarean delivery,^{25,31–33} three for cardiovascular surgery,^{24,34,35} two for orthopaedic surgery,^{19,36} one for gynaecological surgery,⁴¹ and one for laparotomy.²⁸ All these surgical procedures are class 1 (clean) surgery except for laparotomy, for which the details of the specific surgical procedures were not specified in the report. Six trials recommended subcuticular sutures^{19,24,25,28,32,34} and four^{31,35–37} showed equivalent results for sutures and staples. Only one trial recommended staples.³³ Most were small-scale trials (n=48–435). The number of patients in the trials with equivalent results ranged from 77 to 187. Three^{23,38,39} of the four meta-analyses about caesarean delivery recommended subcuticular sutures; the other showed similar outcomes with sutures and staples.⁴⁰ A meta-analysis²¹ of cardiovascular surgery recommended subcuticular sutures to reduce the number of wound complications. We identified no randomised trials in gastrointestinal surgery.

Interpretation

To our knowledge, our trial is the first done in gastrointestinal surgery (a class 2 surgery). Although the results of most randomised trials done in class 1 surgery support the use of subcuticular sutures to reduce wound complications and improve cosmetic outcomes, the benefits of subcuticular sutures in clean-contaminated surgeries remain unclear. This trial failed to prove subcuticular sutures were a new standard procedure for skin closure after gastrointestinal surgery; however, the formation of hypertrophic scars was significantly reduced with subcuticular sutures compared with staples.

satisfaction,^{24,25} and wound handling.^{24,25} Nevertheless, we did not assess patients' satisfaction, patients' preference, or potential overall effects on the health-care system, and we did not use a validated scale to assess scars. We did not directly compare costs either, but the price of one stapling device and that of two packs of PDS-II sutures were roughly the same and median operative time was 10 min longer in the subcuticular sutures group (table 1).

In conclusion, the efficacy of subcuticular sutures was not validated as an improvement over a standard procedure for skin closure after gastrointestinal surgery.

Contributors

TT and KY drafted the paper. TT designed the protocol. YD and MM supervised the design of the trial and assisted with doing the trial. SK and TS obtained and analysed the data. TT, KU, and TI were the main investigators. All other authors participated in study conduct and recruitment of patients.

Clinical Study Group of Osaka University on Risk Management

Hannan Chuo Hospital, Higashiosaka City General Hospital, Ikeda City Hospital, Itami City Hospital, Kansai Rosai Hospital, Kinki Central Hospital of the Mutual Aid Association of Public School Teachers, Moriguchi Keijinkai Hospital, National Hospital Organization Kure Medical Center, National Hospital Organization Osaka National Hospital, Nishinomiya Municipal Central Hospital, Nissei Hospital, NTT WEST Osaka Hospital, Osaka General Medical Center, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka Rosai Hospital, Osaka Seamen's Insurance Hospital, Osaka University, Osaka-Kouseinenkin-Hospital, Otemae Hospital, Rinku General Medical Center, Sakai Municipal Hospital, Tane General Hospital, Toyonaka Municipal Hospital, and Yao Municipal Hospital.

Conflicts of interest

We declare that we have no conflicts of interest.

Acknowledgments

This study was partly funded by Johnson & Johnson. We thank Satoshi Morita (Yokohama City University) for his valuable advice on statistical analysis and interpretation. Data collection was supported by Media Planning).

For more on Media Planning see
http://www.mediapng.co.jp

References

- Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. *Infect Control Hosp Epidemiol* 1999; 20: 725–30.
- Perencevich EN, Sands KE, Cosgrove SE, Guadagnoli E, Meara E, Platt R. Health and economic impact of surgical site infections diagnosed after hospital discharge. *Emerg Infect Dis* 2003; 9: 196–203.
- Smyth ET, Emmerson AM. Surgical site infection surveillance. *J Hosp Infect* 2000; 45: 173–84.
- Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Clin Infect Dis* 2004; 38: 1706–15.
- Leaper D, Burman-Roy S, Palanca A, et al. Prevention and treatment of surgical site infection: summary of NICE guidance. *BMJ* 2008; 337: a1924.
- Hawn MT, Vick CC, Richman J, et al. Surgical site infection prevention: time to move beyond the surgical care improvement program. *Ann Surg* 2011; 254: 494–99.
- Reid K, Pockney P, Draganic B, Smith SR. Barrier wound protection decreases surgical site infection in open elective colorectal surgery: a randomized clinical trial. *Dis Colon Rectum* 2010; 53: 1374–80.
- Chu CC, Williams DF. Effects of physical configuration and chemical structure of suture materials on bacterial adhesion. A possible link to wound infection. *Am J Surg* 1984; 147: 197–204.
- Togo S, Kubota T, Takahashi T, et al. Usefulness of absorbable sutures in preventing surgical site infection in hepatectomy. *J Gastrointest Surg* 2008; 12: 1041–46.
- Cervantes-Sánchez CR, Gutiérrez-Vega R, Vázquez-Carpizo JA, Clark P, Athié-Gutiérrez C. Syringe pressure irrigation of subdermic tissue after appendectomy to decrease the incidence of postoperative wound infection. *World J Surg* 2000; 24: 38–41.
- Nikfarjam M, Kimchi ET, Gusani NJ, Avella DM, Shereef S, Staveley-O'Carroll KF. Reduction of surgical site infections by use of pulsatile lavage irrigation after prolonged intra-abdominal surgical procedures. *Am J Surg* 2009; 198: 381–86.
- Wang ZX, Jiang CP, Cao Y, Ding YT. Systemic review and meta-analysis of triclosan-coated sutures for the prevention of surgical-site infection. *Br J Surg* 2013; 100: 465–73.
- Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. *JAMA* 2001; 286: 944–53.
- Talbot TR. Diabetes mellitus and cardiothoracic surgical site infections. *Am J Infect Control* 2005; 33: 353–59.
- Smith RL, Bohl JK, McElearney ST, et al. Wound infection after elective colorectal resection. *Ann Surg* 2004; 239: 599–605.
- Fisher GT, Fisher JB, Stark RB. Origin of the use of subcuticular sutures. *Ann Plast Surg* 1980; 4: 144–48.
- Taube M, Porter RJ, Lord PH. A combination of subcuticular suture and sterile micropore tape compared with conventional interrupted sutures for skin closure. A controlled trial. *Ann R Coll Surg Engl* 1983; 65: 164–67.
- Inotsume-Kojima Y, Uchida T, Abe M, Doi T, Kanayama N. A combination of subcuticular sutures and a drain for skin closure reduces wound complications in obese women undergoing surgery using vertical incisions. *J Hosp Infect* 2011; 77: 162–65.
- Shetty AA, Kumar VS, Morgan-Hough C, Georgeu GA, James KD, Nicholl JE. Comparing wound complication rates following closure of hip wounds with metallic skin staples or subcuticular vicryl suture: a prospective randomised trial. *J Orthop Surg* 2004; 12: 191–93.
- Angelini GD, Butchart EG, Armistead SH, Breckenridge IM. Comparative study of leg wound skin closure in coronary artery bypass graft operations. *Thorax* 1984; 39: 942–45.
- Sanni A, Dunning J. Staples or sutures for chest and leg wounds following cardiovascular surgery. *Interact Cardiovasc Thorac Surg* 2007; 6: 243–46.
- Johnson A, Young D, Reilly J. Caesarean section surgical site infection surveillance. *J Hosp Infect* 2006; 64: 30–35.
- Clay FS, Walsh CA, Walsh SR. Staples vs subcuticular sutures for skin closure at cesarean delivery: a metaanalysis of randomized controlled trials. *Am J Obstet Gynecol* 2011; 204: 378–83.
- Johnson RG, Cohn WE, Thurer RL, McCarthy JR, Sirois CA, Weintraub RM. Cutaneous closure after cardiac operations: a controlled, randomized, prospective comparison of intradermal versus staple closures. *Ann Surg* 1997; 226: 606–12.
- Basha SL, Rochon ML, Quiñones JN, Coassolo KM, Rust OA, Smulian JC. Randomized controlled trial of wound complication rates of subcuticular suture vs staples for skin closure at cesarean delivery. *Am J Obstet Gynecol* 2010; 203: 285.
- Watanabe A, Kohnoe S, Shimabukuro R, et al. Risk factors associated with surgical site infection in upper and lower gastrointestinal surgery. *Surg Today* 2008; 38: 404–12.
- Ortega G, Rhee DS, Papandria DJ, et al. An evaluation of surgical site infections by wound classification system using the ACS-NSQIP. *J Surg Res* 2012; 174: 33–38.
- Ranaboldo CJ, Rowe-Jones DC. Closure of laparotomy wounds: skin staples versus sutures. *Br J Surg* 1992; 79: 1172–73.
- Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1999; 20: 250–78.
- American Society of Anesthesiologists. New classification of physical status. *Anesthesiology* 1963; 24: 11.
- Moreno E-O A, Davenport DL, Hundley JC, Daily MF, Gedaly R. Predictors of surgical site infection after liver resection: a multicentre analysis using National Surgical Quality Improvement Program data. *HPB (Oxford)* 2012; 14: 136–41.
- Sugiura T, Uesaka K, Ohmagari N, Kanemoto H, Mizuno T. Risk factor of surgical site infection after pancreaticoduodenectomy. *World J Surg* 2012; 36: 2888–94.
- Naotake F, Minoru M, Tetsuya K, Seryon Y, Ken H, Hideyuki S. Cohort study of wound infection for benign hepato-biliary disease with open laparotomies. *Hepatogastroenterology* 2010; 57: 1024–28.
- Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. *Arch Surg* 2005; 140: 174–82.
- Cromi A, Ghezzi F, Gottardi A, Cherubino M, Uccella S, Valdatta L. Cosmetic outcomes of various skin closure methods following cesarean delivery: a randomized trial. *Am J Obstet Gynecol* 2010; 203: e1–8.
- Frishman GN, Schwartz T, Hogan JW. Closure of Pfannenstiel skin incisions. Staples vs subcuticular suture. *J Reprod Med* 1997; 42: 627–30.
- Rousseau JA, Girard K, Turcot-Lemay L, Thomas N. A randomized study comparing skin closure in cesarean sections: staples vs subcuticular sutures. *Am J Obstet Gynecol* 2009; 200: e1–4.
- Chughtai T, Chen LQ, Salasidis G, Nguyen D, Tchervenkov C, Morin JF. Clips versus suture technique: is there a difference? *Can J Cardiol* 2000; 16: 1403–07.
- Mullen JC, Bentley MJ, Mong K, et al. Reduction of leg wound infections following coronary artery bypass surgery. *Can J Cardiol* 1999; 15: 65–68.
- Khan RJ, Fick D, Yao F, et al. A comparison of three methods of wound closure following arthroplasty: a prospective, randomised, controlled trial. *J Bone Joint Surg Br* 2006; 88: 238–42.
- Obermair A, Crandon A, Perrin L, Walsh T, Carrazo M, Nicklin J. Randomized trial of skin closure after laparotomy for gynaecological surgery. *ANZ J Surg* 2007; 77: 460–63.
- Alderdice F, McKenna D, Dornan J. Techniques and materials for skin closure in caesarean section. *Cochrane Database Syst Rev* 2003; 2: CD003577.
- Tuuli MG, Rampersad RM, Carbone JF, Stamilio D, Macones GA, Odibo AO. Staples compared with subcuticular suture for skin closure after cesarean delivery: a systematic review and meta-analysis. *Obstet Gynecol* 2011; 117: 682–90.
- Mackeen AD, Berghella V, Larsen ML. Techniques and materials for skin closure in caesarean section. *Cochrane Database Syst Rev* 2012; 11: CD003577.